Episode Details
Back to EpisodesSanofi (SNY): The Great Recalibration – Pursuing “Pure-Play” Premium in a Post-Conglomerate Era
Published 3 weeks, 1 day ago
Description
Slide Deck 1. Executive Summary: The “Play to Win” Paradox Sanofi enters the fiscal year 2026 at a defining inflection point in its corporate history, characterized by a radical architectural transformation from a diversified healthcare conglomerate into a focused, pure-play biopharmaceutical entity. The fiscal year 2025 served as the crucible for this strategy, witnessing the […]